Techspace One and Two

Sci-Tech Daresbury on site with next phase

Galliford Try has started construction on the 56,000 sq ft next phase of offices and laboratories at Sci-Tech Daresbury, the 250-acre science and innovation enterprise zone in Cheshire.

The space will be delivered across two buildings, Techspace One and Techspace Two.

Techspace One is a three-storey 46,000 sq ft building made up of offices along with wet and dry laboratory facilities, each on its own separate floor.

It is expected to attract companies from sectors such as biomedical, material science and clean technology.

Techspace Two is a two-storey self-contained office building providing 10,000 sq ft which could be divided into a maximum of four individual suites, each with its own entrance.

Work on the developments is expected to be completed by summer 2016.

Sci-Tech Daresbury is a joint venture between Halton Council, Langtree Property Partners and the Science & Technology Facilities Council. The universities of Lancaster, Liverpool and Manchester are all active on the site.

The campus was awarded enterprise zone status in April 2012, allowing occupiers business rate relief, as well as funding for infrastructure and more relaxed planning regulation. The site houses more than 100 high-tech businesses working in research and development.

The enterprise zone status of both buildings means that tenants will be eligible to benefit from five years’ relief on local authority business rates.

John Downes, chief executive of Langtree Property Partners, said: “The start of work on Techspace One and Techspace Two marks a significant milestone in the future growth of Sci-Tech Daresbury. It will further strengthen our status as a location of choice for businesses wishing to benefit from a unique combination of office, research and science facilities as they bring new innovations to market.”

Techspace One has been supported with a grant from the Regional Growth Fund while Techspace Two is supported with a grant from the European Regional Development Fund.

Your Comments

Subscribe to our newsletter